摘要
目的分析研讨阿替普酶治疗急性脑梗死的效果以及其对炎性因子的影响。方法随机从本院2016年6月至2017年7月收治的急性脑梗死患者中抽取60例进行研究,用随机数字法将其分为对照组和研究组,各30例。对照组非溶栓治疗,研究组阿替普酶静脉溶栓治疗,观察比较治疗效果。结果 研究组治疗总疗效93.33%,高于对照组的63.33%(P<0.05)。治疗前,两组炎性因子指标比较,差异无统计学意义(均P>0.05);治疗后,研究组TNF-α(1.72±0.17)ng/L、IL-6(63.85±12.57)ng/L、hs-CRP(8.99±3.15)mg/L,均低于对照组的(2.01±0.22)ng/L、(74.96±13.99)ng/L、(12.15±3.84)mg/L,IL-10(3.53±0.79)ng/ml,高于对照组的(2.96±0.72)ng/ml(均P<0.05)。治疗前,两组NIHSS评分、Barthel指数比较,差异无统计学意义(均P>0.05);治疗后,研究组NIHSS评分低于对照组,Barthel指数高于对照组(均P<0.05)。两组均未发生严重不良反应,对照组1例发生恶心呕吐,研究组1例发生恶心呕吐,停药后均自行缓解。结论 临床治疗急性脑梗死可考虑首选阿替普酶药物,在调节炎性因子指标上作用更突出,进而提升疗效,值得推广。
Objective To analyze and discuss the effect of ateplase on acute cerebral infarction and its influence on inflammatory factors. Methods 60 patients with acute cerebral infarction who were treated in our hospital from June, 2016 to July, 2017 were randomly selected for the study, and were divided into a control group and a study group, 30 cases for each group. The control group was treated by non-thrombolytic therapy, and the study group by intravenous thrombolysis with ateplase. The treatment effects were observed and compared. Results The total clinical effective rate was 93.33% in the study group, and was 63.33% in the control group (P < 0.05). There were no statistical differences in the inflammatory factors between the two groups before the treatment (all P > 0.05). After the treatment, the levels of TNF-α, IL-6, hs-CRP, and IL-10 were (1.72±0.17) ng/L,(63.85±12.57) ng/L,(8.99±3.15) mg/L, and (3.53±0.79) ng/ml in the study group, and were (2.01±0.22) ng/L,(74.96±13.99) ng/L,(12.15±3.84) mg/L, and (2.96±0.72) ng/ml in the control group (all P < 0.05). There were no statistical differences in the NIHSS score and the Barthel index between the two groups before the treatment (both P > 0.05). After the treatment, the NIHSS score was lower and Barthel index was higher in the study group than in the control group (both P < 0.05). No serious adverse reactions occurred in both groups;only 1 case had nausea and vomiting in the control group, and 1 case in the study group, and both were relieved after withdrawal. Conclusion In the treatment of acute cerebral infarction, the first choice of ateplase is considered;it plays a more prominent role in regulating inflammatory factors, and thus improves the clinical effect, so it is worth for promotion.
作者
刘伟娜
Liu Weina(Department of Brain Diseases,Jiamusi Hospital of Traditional Chinese Medicine,Jiamusi 154000,China)
出处
《国际医药卫生导报》
2019年第15期2554-2557,共4页
International Medicine and Health Guidance News
关键词
阿替普酶
急性脑梗死
炎性因子
Ateplase
Acute cerebral infarction
Inflammatory factors
